PolyPid Announces Cost Reduction Plan
Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3…
News
Arbor Biotechnologies’ CEO Devyn Smith, Ph.D., Elected as Chairman of the Alliance for Regenerative Medicine
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Arbor Biotechnologies, a biotechnology company discovering and…
Arbor Biotechnologies’ CEO Devyn Smith, Ph.D., Elected as Chairman of the Alliance for Regenerative Medicine
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Arbor Biotechnologies, a biotechnology company discovering and…
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed…
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed…
SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal
SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development…
SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal
SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development…
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq: TALS),…
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq: TALS),…
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader…
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader…
Societal CDMO Announces Signing of Multiple New CDMO Service Agreements
Agreements Showcase Company’s Ability to Support Novel Therapeutic Programs Regardless of Development Stage; Services Focused…
Societal CDMO Announces Signing of Multiple New CDMO Service Agreements
Agreements Showcase Company’s Ability to Support Novel Therapeutic Programs Regardless of Development Stage; Services Focused…
Foghorn Therapeutics to Present at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage…
Foghorn Therapeutics to Present at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage…
atai Life Sciences Announces R&D Day Agenda
NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (NASDAQ:…
atai Life Sciences Announces R&D Day Agenda
NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (NASDAQ:…
Immuneering Appoints Leah R. Neufeld as Chief People Officer
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company…